Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice.
Inhibiting vascular endothelial growth factor (VEGF) is a therapeutic option in diabetic microangiopathy. However, VEGF is needed at physiological concentrations to maintain glomerular integrity; complete VEGF blockade has deleterious effects on glomerular structure and function. Anti-VEGF therapy i...
Saved in:
| Main Authors: | Florence Njau, Nelli Shushakova, Heiko Schenk, Vera Christine Wulfmeyer, Robin Bollin, Jan Menne, Hermann Haller |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0218494&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Calcium dobesilate – a perfect stranger
by: V. Yu. Bogachev, et al.
Published: (2020-06-01) -
Effect of calcium dobesilate on macular microvasculature in patients with diabetic retinopathy.
by: Jung-Tae Kim, et al.
Published: (2025-01-01) -
Effect of calcium dobesilate on macular microvasculature in patients with diabetic retinopathy
by: Jung-Tae Kim, et al.
Published: (2025-01-01) -
6×His Promotes Binding of a Recombinant Protein to Heparan Sulfate
by: H. Marie Lacy, et al.
Published: (2002-02-01) -
Profiling Heparan Sulfate Proteoglycans in Ovarian Carcinoma
by: Andrew R. Clamp, et al.
Published: (2005-01-01)